905302-42-3 Usage
Uses
Used in Surfactant Production:
15-(tert-butoxy)-15-oxopentadecanoic acid is used as a raw material for the production of surfactants due to its ability to reduce surface tension between liquids and solids, enhancing the effectiveness of cleaning and emulsifying agents.
Used in Emulsifier Formulation:
In the cosmetic industry, 15-(tert-butoxy)-15-oxopentadecanoic acid is used as an emulsifier to stabilize mixtures of oil and water, which is crucial for the creation of creams, lotions, and other skincare products that require a stable emulsion.
Used in Stabilizer Development:
15-(tert-butoxy)-15-oxopentadecanoic acid serves as a stabilizer in various formulations to maintain the consistency and integrity of products over time, preventing separation of ingredients and ensuring a uniform texture.
Used in Personal Care Products:
15-(tert-butoxy)-15-oxopentadecanoic acid is used as an ingredient in personal care products for its antimicrobial properties, helping to protect against microbial contamination and supporting product safety and efficacy.
Used in Healthcare Products:
In healthcare applications, 15-(tert-butoxy)-15-oxopentadecanoic acid is utilized for its antioxidant properties, which can help to neutralize free radicals and protect against oxidative stress, contributing to the overall health and longevity of medical products.
Check Digit Verification of cas no
The CAS Registry Mumber 905302-42-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,5,3,0 and 2 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 905302-42:
(8*9)+(7*0)+(6*5)+(5*3)+(4*0)+(3*2)+(2*4)+(1*2)=133
133 % 10 = 3
So 905302-42-3 is a valid CAS Registry Number.
905302-42-3Relevant academic research and scientific papers
MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF
-
Paragraph 0350-0351, (2018/08/25)
The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
